domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md

@@ -37,6 +37,12 @@ Abridge's clinical outcomes data shows 73% reduction in after-hours documentatio
 
 Epic launched AI Charting in February 2026, creating an immediate commoditization threat to standalone ambient AI platforms. Abridge's response - pivoting to 'more than a scribe' positioning with coding, prior auth automation, and clinical decision support - suggests leadership recognized the documentation beachhead may not be defensible against EHR-native solutions. The timing of this strategic pivot (2025-2026) indicates the scribe adoption success may have a shorter durability window than the 92% adoption figure suggests.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-01-bvp-state-of-health-ai-2026]] | Added: 2026-03-16*
+
+The 92% figure applies to 'deploying, implementing, or piloting' ambient AI as of March 2025, not active deployment. This includes very early-stage pilots. The scope distinction between pilot programs and daily clinical workflow integration is significant — the claim may overstate actual adoption if interpreted as active use rather than organizational commitment to explore the technology.
+
 ---
 
 Relevant Notes:

domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md

@@ -32,6 +32,12 @@ Since [[healthcares defensible layer is where atoms become bits because physical
 
 Abridge reached $100M ARR with 150+ health system customers by May 2025, achieving $5.3B valuation. This represents the clearest real-world validation of AI-native productivity claims in healthcare - a documentation platform scaling to 9-figure revenue without the linear headcount scaling that would be required for traditional medical transcription or documentation services.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-bvp-state-of-health-ai-2026]] | Added: 2026-03-16*
+
+BVP reports AI-native healthcare companies achieve $500K-$1M+ ARR per FTE with 70-80%+ software-like margins, compared to $100-200K for traditional healthcare services and $200-400K for pre-AI healthcare SaaS. This is the primary source for the productivity claim, providing the specific ranges that support the 3-5x multiplier.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -61,22 +61,28 @@ The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (8
 
 
 ### Additional Evidence (challenge)
-*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16*
 
 The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE healthcare costs in elderly populations: muscle loss during treatment + high discontinuation (64.8% at 1 year) + preferential fat regain = sarcopenic obesity → increased fall risk, fractures, disability, and long-term care needs. This directly challenges the Medicare cost-savings thesis by creating NEW healthcare costs (disability, falls, fractures) that may offset cardiovascular and metabolic savings.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+*Source: 2025-12-01-who-glp1-global-guidelines-obesity | Added: 2026-03-16*
 
 WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems.
 
 
 ### Additional Evidence (challenge)
-*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16*
+*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16*
 
 Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+
+BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -55,16 +55,22 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16*
 
 The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16*
+*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16*
 
 Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+
+BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.
+
 ---
 
 Relevant Notes:

domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md

@@ -19,6 +19,12 @@ The emerging consensus: healthcare AI is a platform shift, not a bubble, but the
 
 **Bessemer corroboration (January 2026):** 527 VC deals in 2025 totaling an estimated $14B deployed. Average deal size increased 42% year-over-year (from $20.7M to $29.3M). Series D+ valuations jumped 63%. AI companies captured 55% of health tech funding (up from 37% in 2024). For every $1 invested in AI broadly, $0.22 goes to healthcare AI — exceeding healthcare's 18% GDP share. The Health Tech 2.0 IPO wave produced 6 companies with $36.6B combined market cap, averaging 67% annualized revenue growth. Health tech M&A hit 400 deals in 2025 (up from 350 in 2024), with strategic acquirers consolidating AI capabilities.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-bvp-state-of-health-ai-2026]] | Added: 2026-03-16*
+
+Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series C at $1.04B valuation by early 2026, demonstrating the capital concentration in category leaders. Function Health's $300M Series C at $2.2B valuation further confirms winner-take-most dynamics in health AI.
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -37,16 +37,22 @@ Medicare Advantage plans bearing full capitated risk increased GLP-1 prior autho
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-16*
+*Source: 2025-03-17-norc-pace-market-assessment-for-profit-expansion | Added: 2026-03-16*
 
 PACE represents the 100% risk endpoint—full capitation for all medical, social, and psychiatric needs, entirely replacing Medicare and Medicaid cards. Yet even at full risk with proven outcomes for the highest-cost patients, PACE serves only 0.13% of Medicare eligibles after 50 years. This suggests the stall point is not just at the payment boundary (partial vs full risk) but at the scaling boundary—capital, awareness, regulatory, and operational barriers prevent even successful full-risk models from achieving market penetration. The gap between 14% bearing full risk and PACE's 0.13% penetration indicates that moving from partial to full risk is necessary but insufficient for VBC transformation.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16*
+*Source: 2025-12-23-cms-balance-model-glp1-obesity-coverage | Added: 2026-03-16*
 
 The BALANCE Model moves payment toward genuine risk by adjusting capitated rates for obesity and increasing government reinsurance for participating MA plans. This creates a direct financial incentive mechanism where plans profit from preventing obesity-related complications rather than just managing them. The model explicitly tests whether combining medication access with lifestyle supports under risk-bearing arrangements can shift the payment boundary.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+
+CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2026-02-01-cms-balance-model-details-rfa-design.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "cms-balance-capitation-adjustment-plus-reinsurance-removes-structural-barriers-to-glp1-coverage.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "manufacturer-funded-lifestyle-support-shifts-behavioral-intervention-costs-from-payers-to-drugmakers.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "cms-balance-capitation-adjustment-plus-reinsurance-removes-structural-barriers-to-glp1-coverage.md:set_created:2026-03-16",
+      "manufacturer-funded-lifestyle-support-shifts-behavioral-intervention-costs-from-payers-to-drugmakers.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "cms-balance-capitation-adjustment-plus-reinsurance-removes-structural-barriers-to-glp1-coverage.md:missing_attribution_extractor",
+      "manufacturer-funded-lifestyle-support-shifts-behavioral-intervention-costs-from-payers-to-drugmakers.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2026-01-01-bvp-state-of-health-ai-2026.md

@@ -7,9 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: industry-report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [health-ai, ai-native, revenue-productivity, ambient-scribes, clinical-ai, market-analysis, venture-capital]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -63,3 +67,13 @@ Comprehensive annual landscape analysis of AI in healthcare from Bessemer Ventur
 PRIMARY CONNECTION: [[AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output]]
 WHY ARCHIVED: Primary source for the existing KB productivity claim, plus the scope qualification issue on the 92% adoption figure
 EXTRACTION HINT: Note the scope qualification needed — 92% "deploying/implementing/piloting" vs. active deployment is a meaningful distinction. The extractor should flag this when reviewing the existing KB claim.
+
+
+## Key Facts
+- Traditional healthcare services: $100-200K ARR per FTE
+- Healthcare SaaS (pre-AI): $200-400K ARR per FTE
+- AI-native healthcare: $500K-$1M+ ARR per FTE
+- AI-native healthcare companies achieve 70-80%+ software-like margins
+- As of March 2025: 92% of provider health systems deploying, implementing, or piloting ambient AI
+- Early ambient AI adopters report 10-15% revenue capture improvements through better coding and documentation in year 1
+- Health tech companies hitting $100M+ ARR in under 5 years represents compression of time-to-scale

inbox/archive/2026-02-01-cms-balance-model-details-rfa-design.md

@@ -7,9 +7,13 @@ date: 2026-01-08
 domain: health
 secondary_domains: [internet-finance]
 format: policy-document
-status: unprocessed
+status: enrichment
 priority: high
 tags: [balance-model, cms, glp-1, capitation, medicaid, medicare, value-based-care, lifestyle-support, manufacturer, adherence]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -68,3 +72,13 @@ This is CMS explicitly designing around the misalignment I identified in March 1
 PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 WHY ARCHIVED: The BALANCE model's specific payment mechanism (capitation adjustment + reinsurance) is a direct policy response to the identified VBC misalignment — this design detail changes the analysis from "BALANCE is just drug coverage" to "BALANCE is structural incentive redesign"
 EXTRACTION HINT: Focus on the dual payment mechanism as the structural innovation, not the drug access expansion (which is the headline but not the analytically important insight)
+
+
+## Key Facts
+- BALANCE Model eligibility requires BMI thresholds per FDA labeling plus evidence of metabolic dysfunction (heart failure, uncontrolled hypertension, pre-diabetes)
+- Prior authorization requirements are negotiated with manufacturers, not blanket coverage
+- Manufacturers must reach 'Key Terms' agreement with CMS to become model participants
+- Medicare GLP-1 Bridge launches July 2026, earlier than full BALANCE rollout
+- Bridge provides access to manufacturer-negotiated prices before full model launches
+- State and plan participation is voluntary, creating potential adverse selection risk
+- 9.5% average body weight reduction is the manufacturer eligibility threshold